Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 2, 2014, Pages 339-352

  De Bruyn, Magali ^a,b   Machiels, Kathleen ^a   Vandooren, Jennifer ^b   Lemmens, Bart ^c   Van Lommel, Leentje ^d   Breynaert, Christine ^a   Van Der Goten, Jan ^a   Staelens, Dominiek ^a   Billiet, Thomas ^a   De Hertogh, Gert ^c   Ferrante, Marc ^a   Van Assche, Gert ^a   Vermeire, Séverine ^a   Opdenakker, Ghislain ^b   Schuit, Frans ^d   Rutgeerts, Paul ^a,e   Arijs, Ingrid ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^d Gene Expression Unit   (Belgium)

^e LEUVEN FOOD SCIENCE AND NUTRITION RESEARCH CENTRE LFORCE   (Belgium)

Author keywords

Inflammatory bowel disease; Infliximab; Mucosal expression; Tissue remodeling genes

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DYSFUNCTIONAL MATRIX REMODELING PROTEIN; GELATIN; GELATINASE; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERSTITIAL COLLAGENASE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PROTEIN; STROMELYSIN; UNCLASSIFIED DRUG; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; RNA; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; ASSAY; CONTROLLED STUDY; DEGRADATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUNG ADULT; ZYMOGRAPHY; AGED; ANTAGONISTS AND INHIBITORS; BIOPSY; BIOSYNTHESIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTESTINAL MUCOSA; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84893769989     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000438430.15553.90     Document Type: Article

References (39)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
2. Kusugami K, Nobata K, Tsuzuki T, et al. Mucosal expression of matrix metalloproteinases and their tissue inhibitors in ulcerative colitis patients. J Gastroenterol. 2003;38:412-413.
3. Hu J, Van den Steen PE, Sang QX, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6:480-498.
4. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis. 2007;13:97-107.
5. Rath T, Roderfeld M, Halwe JM, et al. Cellular sources of MMP-7, MMP- 13 and MMP-28 in ulcerative colitis. Scand J Gastroenterol. 2010;45: 1186-1196.
6. Makitalo L, Kolho KL, Karikoski R, et al. Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol. 2010;45: 862-871.
7. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis. 1999;5:44-60.
8. Burke JP, Mulsow JJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448.
9. Opdenakker G, Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol Today. 1994;15:103-107.
10. Van den Steen PE, Dubois B, Nelissen I, et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002;37:375-536.
11. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182-1197.
12. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000; 47:404-409.
13. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
14. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
15. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612-1619.
16. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
17. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
18. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;85:289-300.
20. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 2001;29:e45.
21. Vandooren J, Geurts N, Martens E, et al. Zymography methods for visualizing hydrolytic enzymes. Nat Methods. 2013;10:211-220.
22. Descamps FJ, Martens E, Opdenakker G. Analysis of gelatinases in complex biological fluids and tissue extracts. Lab Invest. 2002;82: 1607-1608.
23. Vandooren J, Geurts N, Martens E, et al. Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain. World J Biol Chem. 2011;2:14-24.
24. Barahona-Garrido J, Hernandez-Calleros J, Garcia-Juarez I, et al. Growth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility. Saudi J Gastroenterol. 2009;15:208-212.
25. Stenson WF. Mechanisms of tissue protection and repair in inflammatory bowel disease. Curr Opin Gastroenterol. 2001;17:313-317.
26. Clark PM, Dawany N, Dampier W, et al. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases. Inflamm Bowel Dis. 2012;18: 2315-2333.
27. Park JY, Kim SA, Chung JW, et al. Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer. J Cancer Res Clin Oncol. 2011;137:1229-1238.
28. Planas R, Pujol-Autonell I, Ruiz E, et al. Regenerating gene Ialpha is a biomarker for diagnosis and monitoring of celiac disease: a preliminary study. Transl Res. 2011;158:140-145.
29. Astorri E, Guglielmi C, Bombardieri M, et al. Circulating Reg1alpha proteins and autoantibodies to Reg1alpha proteins as biomarkers of beta-cell regeneration and damage in type 1 diabetes. Horm Metab Res. 2010;42:955-960.
30. Sekikawa A, Fukui H, Fujii S, et al. Possible role of REG Ialpha protein in ulcerative colitis and colitic cancer. Gut. 2005;54:1437-1444.
31. Dieckgraefe BK, Crimmins DL, Landt V, et al. Expression of the regenerating gene family in inflammatory bowel disease mucosa: Reg Ialpha upregulation, processing, and antiapoptotic activity. J Investig Med. 2002; 50:421-434.
32. Granlund A, Flatberg A, Ostvik AE, et al. Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis. PLoS One. 2013;8:e56818.
33. Garg M, Angus PW, Burrell LM, et al. Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. Aliment Pharmacol Ther. 2012;35:414-428.
34. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis. 2007;39:733-739.
35. Meijer MJ, Mieremet-Ooms MA, van Duijn W, et al. Effect of the antitumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:200-210.
36. Geboes K, Rutgeerts P, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin. 2005;21:1741-1754.
37. Gao Q, Meijer MJ, Schluter UG, et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis. 2007;13:693-702.
38. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63-73.
39. Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010;16:2090-2098.